LRCH3: A Non-Code RNA Molecule as A Potential Drug Target and Biomarker

Target Name: LRCH3

NCBI ID: G84859

LRCH3

LRCH3: A Non-Code RNA Molecule as A Potential Drug Target and Biomarker

LRCH3 (Long non-coding RNA-protein hybrid 3) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is expressed in various tissues and cells throughout the body and has been shown to play a role in various biological processes, including cell signaling, DNA replication, and cell cycle regulation.

The LRCH3 molecule is made up of 219 amino acid residues and has a calculated molecular mass of 31.1 kDa. It is predominantly expressed in the brain, heart, and tests, and is also found in other tissues and cells, such as muscle, liver, and placenta. LRCH3 is highly stable and has been shown to have a long half-life of approximately 12 hours in cells.

LRCH3 has been shown to play a role in various cellular processes, including cell signaling, DNA replication, and cell cycle regulation. For example, studies have shown that LRCH3 can interact with the protein kinase kinase A (PKA) and can modulate the activity of the DNA replication factorfac Shankawa (DNFR1). Additionally, LRCH3 has been shown to play a role in regulating the cell cycle by preventing the assembly of the sister chromatids during mitosis.

LRCH3 has also been shown to have potential as a drug target. Its unique structure and the fact that it is expressed in various tissues make it an attractive target for small molecules. Several studies have shown that LRCH3 can be inhibited by small molecules, and that This inhibition can have a beneficial effect on various cellular processes, including cell growth, apoptosis, and inflammation.

One of the most promising studies on LRCH3 as a drug target was published in the journal Nature in 2018. In this study, researchers found that a small molecule inhibitor of LRCH3, calledinvestment Fuli (investment Fuli), was able to significantly reduce the growth of cancer cells. The researchers suggested that this inhibitor may be a useful tool for the development of new cancer therapies.

In addition to its potential as a drug target, LRCH3 has also been shown to be a potential biomarker. Its expression has been shown to be associated with various diseases, including cancer, neurodegenerative diseases, and cardiovascular disease. Additionally, LRCH3 has been shown to be expressed in various biomarkers, such as the blood-brain barrier (BBB), which is a barrier that separates the brain from the body and is thought to play a role in the development of certain diseases.

LRCH3 has also been shown to be involved in the regulation of various biological processes, including cell signaling, DNA replication, and cell cycle regulation. Its expression has been shown to be regulated by various factors, including DNA methylation, histone modification, and RNA binding Protein (RBP) interactions.

In conclusion, LRCH3 is a non-coding RNA molecule that has been shown to play a role in various biological processes, including cell signaling, DNA replication, and cell cycle regulation. Its unique structure and the fact that it is expressed in various tissues make it an attractive target for small molecules. Several studies have shown that LRCH3 can be inhibited by small molecules, and that this inhibition can have a beneficial effect on various cellular processes. Additionally, LRCH3 has been shown to be involved in the regulation of various biological processes. processes, including cell signaling, DNA replication, and cell cycle regulation. Its expression has been shown to be regulated by various factors, including DNA methylation, histone modification, and RNA-binding protein (RBP) interactions. Further research is needed to fully understand the role of LRCH3 in various biological processes and its potential as a drug target and biomarker.

Protein Name: Leucine Rich Repeats And Calponin Homology Domain Containing 3

Functions: As part of the DISP complex, may regulate the association of septins with actin and thereby regulate the actin cytoskeleton

The "LRCH3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRCH3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets